1. Characteristic requirement 1: a compound, including formula structure (1) or a pharmaceutically acceptable salt, wherein L is a can selected from the direct link group, a C1-6 tree or rectal chain tar, SO2 -.-C (o) NH-And other formulas (2),In this case, the R9 and R10 groups and the carbon atoms connected to them can selectively combine to form a c3-7 cyclododecane； R1 is selected from C1-6 tar or c3-7 cyclododecane； R2 is selected from the group consisting of - co2r9, - C (o) R15 and the residue of the formula group (3)；R3 is selected from C1-6, - or10, R10 (R14) Q, tetrahydrofuran, oxetanio, furanio, dioxolanilo, piranio, dioxanilo, dioxinilo, dioxinilo, - o-cycloquilo c3-7, - cyclo-c3-7 - (R10)；R4 is selected from the group consisting of C5-15 aryl, C3-7 cycloalkyl, C2-9 heterocycle, and C2-9 heteroaryl, wherein the heterocycle and heteroaryl each comprise from one to three heteroatoms selected from the S, N or O, and wherein each R4 group is optionally substituted by one to four substituents selected from R11； R5, R6, and R7 are independently selected from -H, C1-6 alkyl, C1-6 alkoxy, halogen, nitrile, C3-7 cycloalkyl, -OR10-C5-15 aryl, -OR10R14, -OR10-C5 aryl -15, -OR10-aryl C5-14- (R11) m, -OR9, -R10 (Y) - (R12) n, -OR10R17, -R10R17, -R17R15, -OR10 (R14) q, -OR10 (Y ),-OR10R18, -OSO2R15, -R15, -aryl C5-15, - (Y),- (Y) - (R12) n -C (O) - (Y)-C (O) R15, -R10-C5-15 aryl, -R10R15, and -C5-14-R12 aryl, wherein R5 and R6, together with the carbon atoms to which they are bonded, may optionally bond with each other to form a ring of C4-7 cycloalkyl, C2-9 heterocycle, or C5-15 aryl, or alternatively, when L is a bond, R6 and R7, together with the carbon atoms to which they are bonded , can optionally be linked together to form a C3-7 heterocycle or C3-7 cycloalkyl ring； R9 is independently selected from -H and C1-6 alkyl； R10 is C1-6 alkyl； R11, R12, and R13 are independently selected from the group consisting of C1-6 alkyl, C1-6 alkoxy,butoxy-carbonyl, oxo, -R10OR
